Amphastar Pharmaceuticals heads into its third-quarter report with a stock that has already moved well ahead of the fundamentals. Shares have climbed about 17% since the last report while the S&P 500 barely budged. Yet the Street is modeling a quarter in which revenue barely grows and earnings slip. That gap between price momentum and muted estimates is the real story. The question is whether new launches like generic ipratropium can keep outrunning the costs and disruption tied to a fresh FDA warning letter at the company's IMS subsidiary.
Consensus calls for earnings of $0.80 per share on revenue of $194.6 million. That works out to EPS down about 3.6% from $0.83 a year ago, with sales up only 1.4% from $191.8 million. Sequentially the picture looks better. Revenue would rise nearly 6% from the second quarter's $183.9 million, extending the reacceleration that began last quarter. Still, the year-over-year growth estimate sits below the mid-single to high-single digit full-year pace management reaffirmed in August. Either the Street doubts that framework, or it expects the fourth quarter to do the heavy lifting. The outlook has also already been trimmed from the high-single to low-double digit range floated a year earlier. A third quarter that lands near consensus would keep the target alive, but it would leave little cushion.
The IMS warning letter is the newest and most important variable. That operation accounts for roughly a third of corporate sales. Management has said remediation will add $2 million to $3 million in expenses each quarter for several quarters and slightly slow IMS sales. This report offers the first full look at that cost in action. Investors should look for remediation spending that stays within the stated band and no mention of line shutdowns. They should also want evidence that IMS volumes softened only modestly. Any widening of the problem would challenge the idea that this risk is contained.
On the growth side, ipratropium is the swing product. It delivered $8.4 million in its first full quarter as the first and only generic, and management said it was outpacing original assumptions. A further step up would support the thesis that newer products can offset legacy erosion. Iron sucrose, teriparatide and albuterol fall in the same category. Glucagon, down 42% last quarter, remains the drag, and management expects only a slower decline rather than stabilization. Vaximi is the other key test. Prescriptions grew about 17% last quarter, but net sales fell 3% on rebates and 340B duplicate discounts. With the 340B fix roughly halfway to its 80% target, a narrower gap between volume and net revenue would be a meaningful sign of progress. The $100 million milestone payment owed to Lilly this quarter will also affect cash flow.
Margins tie it all together. Gross margin recovered to 51% last quarter, but SG&A and G&A each rose about 30%. Expected EPS decline on rising revenue suggests the Street sees costs absorbing most of the top-line gains. Holding gross margin near last quarter's level while slowing expense growth would be the clearest way to beat.
Sentiment has warmed noticeably, with the bearish reading easing to 28% from 46% ahead of the prior report. The stock trades near $26.33, comfortably above its 200-day average of $22.29. It sits in the upper portion of its post-earnings range, though still about 5% below the $27.80 high. That suggests investors have already credited some of the commercial recovery. The central issue is whether new-product momentum and 340B progress can absorb IMS remediation without further eroding a growth outlook that has already been trimmed once. If they can, the rally has support. If IMS bleeds into sales or margins more than expected, recent gains look exposed.